CARDIFF ONCOLOGY, INC. (CRDF) Free cash flow 2016–2025
CARDIFF ONCOLOGY, INC. (CRDF) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$38.0MFY2025 · since FY2016: -$31.9M → -$38.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$38.0M | -0.5% |
| FY2024 | -$37.8M | -20.0% |
| FY2023 | -$31.5M | +9.6% |
| FY2022 | -$34.8M | -49.8% |
| FY2021 | -$23.2M | -40.7% |
| FY2020 | -$16.5M | -23.9% |
| FY2019 | -$13.3M | -1.0% |
| FY2018 | -$13.2M | +43.5% |
| FY2017 | -$23.4M | +26.6% |
| FY2016 | -$31.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRDF financial trends
CRDF RevenueCRDF Net incomeCRDF Net marginCRDF Gross profitCRDF Gross marginCRDF Operating incomeCRDF Operating marginCRDF Operating cash flowCRDF Capital expendituresCRDF Return on equityCRDF Stock buybacksCRDF Dividends paidCRDF Total assetsCRDF Total liabilitiesCRDF Shareholders’ equityCRDF overview →